15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Atea Pharmaceuticals Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $7.00 to $10.00, a moderate spread. The average target of $8.50 sits 50% above the current $5.67. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.57 next quarter toward $-1.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Atea Pharmaceuticals Inc.
As of Sep, 1 of 2 firms rate AVIR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AVIR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.57
Range $-0.72 – $-0.42 · 2 analysts · +0% YoY
Next period, 2 analysts expect Atea Pharmaceuticals Inc to earn $-0.57 a share (range $-0.72 – $-0.42), versus $-0.57 a year earlier. Full-year consensus is $-1.99, growing to $-1.48 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $30.0M next year.
Top analysts covering Atea Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVIR.
#1
Matthew Harrison
Morgan Stanley · Rank #300
Hold
$7.00+23.5% to target
Overall win rate
45%
+ Follow
#2
UR
Umer Raffat
Evercore ISI
Buy
$10.00+76.4% to target
Coverage
—
+ Follow
#3
JM
Jonathan Miller
Evercore ISI
Buy
$10.00+76.4% to target
Coverage
—
+ Follow
AVIR stock forecast FAQ
What is AVIR's average 12-month price target?+
The 2 analysts with a live target average $8.50 for Atea Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $7.00 low.
Is AVIR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AVIR?+
The Street-high target is $10.00 (Evercore ISI Group), and the Street-low is $7.00 (Morgan Stanley). The average of all 2 active targets is $8.50.
How many Wall Street analysts cover AVIR?+
2 analysts have an active rating on Atea Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering AVIR?+
Among analysts who currently cover AVIR, Matthew Harrison of Morgan Stanley has the strongest overall Quantellect track record (Rank #300). Their current call is Hold with a $7.00 target.
What is Atea Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.57 per share (range $-0.72 – $-0.42) across 2 analysts. Full-year EPS is projected at $-1.99, rising to $-1.48 the following year.
How much revenue is Atea Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $30.0M next year.
Have analysts been upgrading or downgrading AVIR lately?+
As of Sep, 1 of 2 firms rate AVIR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVIR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
